01
Unmet medical need
Whether an application addresses a condition that current care does not serve well. This is a qualitative question for later expert review, not a score.
THERAPEUTIC OPPORTUNITY SCREENING
Our vision. Today, explore the research-prioritisation workspace in demo mode.
Find the right therapeutic application for your platform. Indica Bio is being developed to help teams prioritise therapeutic opportunities by unmet medical need, commercial potential, and the rationale for their delivery approach.
Explore our approachEarly-stage project · LMU Startup in 2 Days
A platform technology can point toward many therapeutic uses. The decision is which applications warrant deeper investigation, given the platform's capabilities, constraints, and potential clinical and commercial relevance.
Indica Bio is being developed so that choice can be made explicit before a team commits to a longer scientific and commercial review.
The question was raised by Prof. Baldauf, Virology, LMU. The team is taking it up during LMU Startup in 2 Days.
Platform research image
INTENDED WORKFLOW
These four steps are the intended workflow. They describe how screening is meant to work. They do not describe a finished product.
01
Capture capabilities, constraints, and intended use.
02
Identify possible therapeutic applications for evaluation.
03
Consider the selected criteria while exposing assumptions and evidence gaps.
04
Develop a shortlist for deeper scientific and commercial review.
These are intentions, not measured outcomes. The workspace does not claim time savings, cost reductions, or lower inference latency.
The example in the brief is prioritising therapeutic proteins. It asks where unmet medical need, commercial potential, and a delivery rationale could justify a closer look.
01
Whether an application addresses a condition that current care does not serve well. This is a qualitative question for later expert review, not a score.
02
Whether an application could support a credible path toward development and adoption. No market size is claimed here.
03
For the protein example, where giving the protein directly could have a specific advantage over an mRNA- or DNA-based approach.
The platform technology, the dataset, how these criteria should be weighted, and what would count as success have not been defined yet.
The project is being shaped for the groups below. They are intended audiences. Indica Bio does not yet have customers.
01
Teams deciding which therapeutic uses of a platform deserve a deeper look.
02
Groups connecting a technology with a clinical question.
03
Teams weighing how a research platform might move toward an application.
04
Teams comparing application paths before a larger commercial review.
The people taking part in LMU Startup in 2 Days. The notes below describe what each person brings to this project.
Portrait to be added
Customer insight. Runs an AI community platform for students.
Portrait to be added
Domain expertise. Founder of Thaevon Biosciences, working in synthetic biology and AI.
Portrait to be added
Builder. Core AI agent systems, with a protein and lipid nanoparticle production and quality-control idea.
Portrait to be added
Sales and business development. Medicine, serial entrepreneurship, and AI × oncology.
A few limits, stated plainly.
A signed-in demonstration workspace is part of this website. It does not run live scientific analysis or protein simulation. Indica Bio is not commercially available, and it has not been scientifically validated as a product.
The intended result is a shortlist of therapeutic applications for deeper scientific and commercial review. It would not be a validated therapeutic recommendation.
No. The relevant comparison depends on the protein, indication, and platform. No delivery modality is assumed to be universally preferable.
No. It is intended for research and commercial assessment. It is not a clinical decision tool, and it does not give medical advice.
We're speaking with researchers and biotech teams about how they identify and prioritise therapeutic applications.
We're preparing our discovery conversations. Contact details will be published here.